NEW YORK – Genetron Health announced Thursday a strategic partnership with Thermo Fisher Scientific to commercialize next-generation sequencing-based diagnostics in China.
The deal will bring the Genetron S5, which is based on Thermo Fisher's Ion GeneStudio S5 instrument for targeted NGS, to China's public hospitals for use in cancer diagnostics, genetic disease diagnosis, microbial testing, and reproductive health testing, among other uses.